Results

1–3 of 3 results for Vascular endothelial growth factor-A (VEGF-A)

Baseline and Early Treatment Response Variables Associated With Faricimab Durability in Treatment-Naive nAMD: TENAYA/LUCERNE Post Hoc Analyses
Benjamin Bakall, MD, PhD
Annual Meeting Talks
2025
Faricimab Rapidly Improves Fluid Parameters in Patients With nAMD
Nikolas JS London, MD, FACS, FASRS
Annual Meeting Talks
2023
Impact of Faricimab vs Aflibercept on Epiretinal Membrane Formation Over 2 Years in Eyes With DME in the YOSEMITE/RHINE Phase 3 Trials
Glenn J. Jaffe, MD
Annual Meeting Talks
2023